ZIM
PDLI

Zacks Investment Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Zacks Investment Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-35,915
Closed -$105K – 592
2020
Q2 		$105K Buy
35,915
+17,995
+100% +$56.9K ﹤0.01% 489
2020
Q1 		$51K Buy
+17,920
New +$57.8K ﹤0.01% 481
2019
Q3 		– Sell
-29,324
Closed -$92K – 622
2019
Q2 		$92K Sell
29,324
-88,055
-75% -$286K ﹤0.01% 516
2019
Q1 		$437K Buy
+117,379
New +$396K 0.01% 465
2015
Q1 		– Sell
-28,621
Closed -$221K – 788
2014
Q4 		$221K Buy
+28,621
New +$227K 0.01% 578

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Zacks Investment Management's PDLI Position: Q3 2020 in Review

Zacks Investment Management sold out of PDL BioPharma, Inc. (PDLI) in Q3 2020, closing a stake of 35,915 shares — an estimated $105K sold.

Zacks Investment Management first reported a position in PDLI in Q4 2014 and held it in 5 quarters. The position peaked at $437K in Q1 2019. 132 funds tracked by Wall St. Rank hold PDLI as of Q3 2020.

  • Zacks Investment Management reported no remaining PDL BioPharma, Inc. position as of Q3 2020 after selling out during the quarter.
  • Zacks Investment Management sold 35,915 PDL BioPharma, Inc. shares in Q3 2020, an estimated $105K.
  • Zacks Investment Management first reported a position in PDL BioPharma, Inc. in Q4 2014 and held it in 5 quarters.
  • Zacks Investment Management's PDL BioPharma, Inc. position peaked at $437K in Q1 2019.
  • 132 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2020.

Based on Zacks Investment Management's 13F filing for Q3 2020, filed 16 Nov 2020.